A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

PURPOSE: Bevacizumab is an antibody against vascular endothelial growth factor (VEGF); sunitinib is an inhibitor of VEGF and related receptors. The safety and maximum tolerated dose (MTD) of sunitinib plus bevacizumab was assessed in this phase I trial. EXPERIMENTAL DESIGN: Patients with advanced so...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rini, Brian I., Garcia, Jorge A., Cooney, Matthew M., Elson, Paul, Tyler, Allison, Beatty, Kristi, Bokar, Joseph, Mekhail, Tarek, Bukowski, R.M., Budd, G. Thomas, Triozzi, Pierre, Borden, Ernest, Ivy, Percy, Chen, Helen X., Dolwati, Afshin, Dreicer, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756318/
https://ncbi.nlm.nih.gov/pubmed/19773375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0717
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados